Efficacy and Safety of Candidate Biosimilar CT-P43 Versus Originator Ustekinumab in Moderate to Severe Plaque Psoriasis: 28-Week Results of a Randomised, Active-Controlled, Double-Blind, Phase III StudyKim Papp, Woori Ko, Yunju Bae et al.|BioDrugs|2023Cited by 30